TY - JOUR
T1 - Consensus conference
T2 - Colorectal cancer screening and surveillance in inflammatory bowel disease
AU - Itzkowitz, Steven H.
AU - Present, Daniel H.
AU - Binder, Vibeke
AU - Boland, C. Richard
AU - Brentnall, Teresa A.
AU - Chutkan, Robynne K.
AU - Cogan, Michael P.
AU - Ekbom, Anders
AU - Ezaki, Toshihiko
AU - Haggitt, Rodger C.
AU - Hisamatsu, Tadakazu
AU - Karlén, Per
AU - Korelitz, Burton I.
AU - Lashner, Bret A.
AU - Loeb, Lawrence
AU - Lennard-Jones, John
AU - Lofberg, Robert
AU - Loftus, Edward V.
PY - 2005/3
Y1 - 2005/3
N2 - The idiopathic inflammatory bowel diseases, ulcerative colitis and Crohn's colitis, are associated with an increased risk for developing colorectal cancer. To reduce colorectal cancer mortality in inflammatory bowel disease, most patients and their physicians choose to follow a program of surveillance colonoscopy in an attempt to detect early neoplastic lesions at a curable stage. Colectomy is typically reserved for patients whose biopsy findings are indicative of heightened cancer risk based on interpretation by pathologists. Despite the absence of prospective controlled clinical trials to formally evaluate the benefits, risks, and costs of this approach, enough circumstantial evidence has accrued to warrant its widespread adoption in practice. Nevertheless, no standardized guidelines have yet been set forth to guide the gastroenterologist in performing surveillance. A panel of international experts was assembled to develop consensus recommendations for the performance of surveillance. The findings are presented herein.
AB - The idiopathic inflammatory bowel diseases, ulcerative colitis and Crohn's colitis, are associated with an increased risk for developing colorectal cancer. To reduce colorectal cancer mortality in inflammatory bowel disease, most patients and their physicians choose to follow a program of surveillance colonoscopy in an attempt to detect early neoplastic lesions at a curable stage. Colectomy is typically reserved for patients whose biopsy findings are indicative of heightened cancer risk based on interpretation by pathologists. Despite the absence of prospective controlled clinical trials to formally evaluate the benefits, risks, and costs of this approach, enough circumstantial evidence has accrued to warrant its widespread adoption in practice. Nevertheless, no standardized guidelines have yet been set forth to guide the gastroenterologist in performing surveillance. A panel of international experts was assembled to develop consensus recommendations for the performance of surveillance. The findings are presented herein.
UR - http://www.scopus.com/inward/record.url?scp=20144388645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20144388645&partnerID=8YFLogxK
U2 - 10.1097/01.MIB.0000160811.76729.d5
DO - 10.1097/01.MIB.0000160811.76729.d5
M3 - Article
C2 - 15735438
AN - SCOPUS:20144388645
SN - 1078-0998
VL - 11
SP - 314
EP - 321
JO - Inflammatory bowel diseases
JF - Inflammatory bowel diseases
IS - 3
ER -